Alnylam Pharma (0HD2) Share Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HD2 Analyst Ratings

Strong Buy

15 Buy

3 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HD2 Stock 12 Month Forecast

Average Price Target

$480.81

▲(38.87% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $480.81 with a high forecast of $580.00 and a low forecast of $351.00. The average price target represents a 38.87% change from the last price of $346.23.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"237":"$237","323":"$323","409":"$409","495":"$495","581":"$581"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":580,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$580.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":480.8125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$480.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":351,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$351.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[237,323,409,495,581],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.239,415.91292307692305,429.5868461538461,443.2607692307692,456.9346923076923,470.60861538461535,484.2825384615385,497.95646153846155,511.6303846153846,525.3043076923077,538.9782307692308,552.6521538461539,566.3260769230769,{"y":580,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.239,408.28311538461537,414.32723076923077,420.37134615384616,426.4154615384615,432.4595769230769,438.5036923076923,444.5478076923077,450.5919230769231,456.6360384615385,462.68015384615387,468.7242692307692,474.7683846153846,{"y":480.8125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.239,398.29753846153847,394.3560769230769,390.4146153846154,386.4731538461538,382.5316923076923,378.59023076923074,374.64876923076923,370.70730769230767,366.76584615384616,362.8243846153846,358.8829230769231,354.94146153846157,{"y":351,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":238.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.733,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.655,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":466.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.465,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.239,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$580.00

Average Price Target$480.81

Lowest Price Target$351.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$570→$510

Buy

47.30%

Upside

Reiterated

01/30/26

Alnylam price target lowered to $510 from $570 at H.C. WainwrightAlnylam price target lowered to $510 from $570 at H.C. Wainwright

Tazeen Ahmad

Bank of America Securities

$529→$462

Buy

33.44%

Upside

Reiterated

01/30/26

Bank of America Securities Remains a Buy on Alnylam Pharma (ALNY)

Michael Ulz

Morgan Stanley

$495→$408

Hold

17.84%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Amgen (NASDAQ: AMGN) and Indivior (NASDAQ: INDV)

Ritu Baral

TD Cowen

$482

Buy

39.21%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

Eliana Merle

Barclays

$527

Buy

52.21%

Upside

Reiterated

01/27/26

Alnylam assumed with an Overweight at BarclaysAlnylam assumed with an Overweight at Barclays

Derek Archila

Wells Fargo

$479→$376

Hold

8.60%

Upside

Reiterated

01/20/26

Wells Fargo Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

Luca Issi

RBC Capital

$500→$465

Buy

34.30%

Upside

Reiterated

01/20/26

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

Cory Kasimov

Evercore ISI

$515

Buy

48.75%

Upside

Reiterated

01/13/26

Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

William Pickering

Bernstein

$525→$491

Buy

41.81%

Upside

Assigned

01/13/26

Bernstein Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

We believe investors had expected fourth-quarter revenue to be below consensus estimates since third-party script data had implied more modest Amvuttra TRx growth and was reflected by the 15% stock decline since December 2025. Therefore, we expect Alnylam shares to trade higher on the strong 2026 TTR franchise guide and 2030 corporate plan outline. Total TTR 2026 revenue guidance of $4,400 million to $4,700 million (83% growth compared to 2025 at the midpoint) is substantially above our estimate of $3,936 million. We have updated our model and now estimate $4,551 million in TTR franchise revenues and $5,124 million in total net product revenues. We provide variance from fourth quarter 2025 estimates in exhibit 1, summarize announced 2026 guidance in exhibit 2, and detail our model updates in exhibit 3.

Joseph Stringer

Needham

$520→$529

Buy

52.79%

Upside

Reiterated

01/12/26

We anticipate the Amvuttra launch in TTR-CM will be a key driver for ALNY shares in 2026. We think the initial revenue guide is highly encouraging and provides some additional room for potential upside in our view. We are updating our models and raising our 2026+ revenue estimates. Raising PT to $529. Disclaimers JOSEPH STRINGER, PH.D.

Paul Matteis

Stifel Nicolaus

$508

Buy

46.72%

Upside

Reiterated

01/12/26

Danielle Brill

Truist Financial

Buy

―

Reiterated

01/12/26

Salveen Richter

Goldman Sachs

$580

Buy

67.52%

Upside

Reiterated

01/12/26

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)

Edward Tenthoff

Piper Sandler

$489

Buy

41.24%

Upside

Reiterated

01/12/26

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$570→$510

Buy

47.30%

Upside

Reiterated

01/30/26

Alnylam price target lowered to $510 from $570 at H.C. WainwrightAlnylam price target lowered to $510 from $570 at H.C. Wainwright

Tazeen Ahmad

Bank of America Securities

$529→$462

Buy

33.44%

Upside

Reiterated

01/30/26

Bank of America Securities Remains a Buy on Alnylam Pharma (ALNY)

Michael Ulz

Morgan Stanley

$495→$408

Hold

17.84%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Amgen (NASDAQ: AMGN) and Indivior (NASDAQ: INDV)

Ritu Baral

TD Cowen

$482

Buy

39.21%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

Eliana Merle

Barclays

$527

Buy

52.21%

Upside

Reiterated

01/27/26

Alnylam assumed with an Overweight at BarclaysAlnylam assumed with an Overweight at Barclays

Derek Archila

Wells Fargo

$479→$376

Hold

8.60%

Upside

Reiterated

01/20/26

Wells Fargo Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

Luca Issi

RBC Capital

$500→$465

Buy

34.30%

Upside

Reiterated

01/20/26

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)

Cory Kasimov

Evercore ISI

$515

Buy

48.75%

Upside

Reiterated

01/13/26

Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

William Pickering

Bernstein

$525→$491

Buy

41.81%

Upside

Assigned

01/13/26

Bernstein Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

Joseph Stringer

Needham

$520→$529

Buy

52.79%

Upside

Reiterated

01/12/26

Paul Matteis

Stifel Nicolaus

$508

Buy

46.72%

Upside

Reiterated

01/12/26

Danielle Brill

Truist Financial

Buy

―

Reiterated

01/12/26

Salveen Richter

Goldman Sachs

$580

Buy

67.52%

Upside

Reiterated

01/12/26

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)

Edward Tenthoff

Piper Sandler

$489

Buy

41.24%

Upside

Reiterated

01/12/26

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months

xxx

Success Rate

20/31 ratings generated profit

Average Return

+8.56%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.52% of your transactions generating a profit, with an average return of +8.56% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

19/23 ratings generated profit

Average Return

+39.61%

reiterated a buy rating 6 months ago

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 82.61% of your transactions generating a profit, with an average return of +39.61% per trade.

2 Years

xxx

Success Rate

22/23 ratings generated profit

Average Return

+70.96%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +70.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HD2 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HD2 has received 25 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 0HD2 average Analyst price target in the past 3 months is 480.81.

Each month's total comprises the sum of three months' worth of ratings.

0HD2 Financial Forecast

0HD2 Earnings Forecast

Next quarter’s earnings estimate for 0HD2 is $1.16 with a range of -$0.45 to $4.34. The previous quarter’s EPS was $1.84. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Sales Forecast

Next quarter’s sales forecast for 0HD2 is $1.15B with a range of $1.04B to $1.61B. The previous quarter’s sales results were $1.25B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Stock Forecast FAQ

What is GB:0HD2’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 480.81.

What is GB:0HD2’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 38.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 480.81. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $580.00 ,and the lowest forecast is $351.00. The average share price target represents 38.87% Increase from the current price of $346.23.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alnylam Pharma (0HD2) Share Forecast & Price Target

0HD2 Analyst Ratings

0HD2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

0HD2 Analyst Recommendation Trends

0HD2 Financial Forecast

0HD2 Earnings Forecast

0HD2 Sales Forecast

0HD2 Stock Forecast FAQ

Detailed List of Analyst Forecasts